Shea replacing Kim as CEO of Inovio
Plus new chief commercial officer at DNA Script, and updates from Boston Pharma, Quantum SI, Beta, Longeveron and more
Jacqueline Shea will succeed J. Joseph Kim as president and CEO of Inovio Pharmaceuticals Inc. (NASDAQ:INO). Shea, who is expected to join the board this month, joined the DNA company as COO in 2019 after serving as CEO of TB non-profit Aeras. Kim has resigned from the board. The company acknowledged that Shea takes the helm at a challenging time for the company. Its stock has fallen 62% in the past year; it was off a further 19% in after-hours trading.
Boston Pharmaceuticals Inc. named Sophie Kornowski as chair and acting CEO. Kornowski succeeds interim co-CEOs Joanne Beck and Craig Basson, who will continue in their roles as COO and CMO, respectively. Kornowski was a partner at Gurnet Point Capital, before which she held leadership roles at Roche (SIX:ROG; OTCQX:RHHBY) for 11 years, including as EVP of partnering...